• Gail D'Onofrio, Kathryn F Hawk, Andrew A Herring, Jeanmarie Perrone, Ethan Cowan, Ryan P McCormack, James Dziura, TaylorR AndrewRAEmergency Medicine, Yale School of Medicine, New Haven, CT, United States., Edouard Coupet, E Jennifer Edelman, Michael V Pantalon, Patricia H Owens, Shara H Martel, Patrick G O'Connor, Paul Van Veldhuisen, Nicholas DeVogel, Kristen Huntley, Sean M Murphy, Michelle R Lofwall, Sharon L Walsh, and David A Fiellin.
• Emergency Medicine, Yale School of Medicine, New Haven, CT, United States; Yale School of Public Health, New Haven, CT, United States. Electronic address: gail.donofrio@yale.edu.
• Contemp Clin Trials. 2021 May 1; 104: 106359.

AbstractED-INNOVATION (Emergency Department-INitiated bupreNOrphine VAlidaTION) is a Hybrid Type-1 Implementation-Effectiveness multisite emergency department (ED) study funded through The Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM efforts to increase access to medications for opioid use disorder (OUD). We use components of Implementation Facilitation to enhance adoption of ED-initiated buprenorphine (BUP) at approximately 30 sites. Subsequently we compare the effectiveness of two BUP formulations, sublingual (SL-BUP) and 7-day extended-release injectable (CAM2038, XR-BUP) in a randomized clinical trial (RCT) of approximately 2000 patients with OUD on the primary outcome of engagement in formal addiction treatment at 7 days. Secondary outcomes assessed at 7 and 30 days include self-reported opioid use, craving and satisfaction, health service utilization, overdose events, and engagement in formal addiction treatment (30 days) and receipt of medications for OUD (at 7 and 30 days). A sample size of 1000 per group provides 90% power at the 2-sided significance level to detect a difference in the primary outcome of 8% and accommodates a 15% dropout rate. We will compare the cost effectiveness of the two treatments on the primary outcome using the incremental cost-effectiveness ratio. We will also conduct an ancillary study in approximately 75 patients experiencing minimal to no opioid withdrawal who will undergo XR-BUP initiation. If the ancillary study demonstrates safety, we will expand the eligibility criteria for the RCT to include individuals with minimal to no opioid withdrawal. The results of these studies will inform implementation of ED-initiated BUP in diverse EDs which has the potential to improve treatment access.Copyright © 2021. Published by Elsevier Inc.

14 keywords...

hide…